Elan's (ELN) chief executive said he believes the multiple sclerosis drug Tysabri, whose sales were suspended after a patient died while taking it, will again be given the green light by regulators.
According to published reports, Kelly Martin said he expects Tysabri to return to the market. Reuters reported that Martin said a safety investigation of the drug should end by mid-to-late summer, after which talks with the Food and Drug Administration could start. Martin spoke to reporters after Elan's annual shareholder meeting in Dublin, the report said. Elan and partner Biogen Idec (BIIB) pulled the drug in February after two people taking the drug contracted a brain disease called progressive multifocal leukoencephalopathy. One died. Tysabri was cleared for marketing by the FDA late last year. Shares of Elan were gaining 96 cents, or 13%, to $8.17. Biogen Idec was up 62 cents to $38.61.>To order reprints of this article, click here: ReprintsTheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,763.05 | 1,339.00 | 2,902.74 | 19.91 |
Oil *
117.19
|
|
DOWN
127.41 |
DOWN
12.95 |
DOWN
24.49 |
DOWN
0.56 |
10 Yr
1.99%
SPDR Gold
166.91
|
|
-0.99%
|
-0.96%
|
-0.84%
|
-2.74%
|
Data delayed 20 minutes |
Connect with TheStreet